Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Kilitch Drugs (India) Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 45 | 37 | 41 | 32 | 45 | 33 | 47 | 56 | 61 | 43 | 49 | 54 | 90 |
| Expenses + | 39 | 30 | 33 | 30 | 38 | 32 | 41 | 47 | 47 | 40 | 44 | 48 | 67 |
| Operating Profit | 6 | 6 | 9 | 2 | 7 | 2 | 6 | 9 | 15 | 3 | 5 | 6 | 22 |
| OPM % | 14% | 17% | 21% | 7% | 16% | 5% | 13% | 16% | 24% | 8% | 10% | 11% | 25% |
| Other Income + | 1 | 1 | 0 | 3 | 0 | 3 | 5 | 2 | 2 | 3 | 7 | 2 | 0 |
| Interest | 1 | 2 | 2 | 2 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 5 | 7 | 3 | 5 | 2 | 10 | 8 | 14 | 3 | 9 | 6 | 20 |
| Tax % | 43% | 33% | 25% | 38% | 31% | 93% | 17% | 32% | 26% | 34% | 14% | 23% | 26% |
| Net Profit + | 3 | 3 | 5 | 2 | 4 | 0 | 9 | 6 | 10 | 2 | 8 | 4 | 15 |
| EPS in Rs | 1.05 | 0.99 | 1.35 | 0.83 | 1.03 | 0.38 | 2.46 | 1.70 | 2.97 | 0.87 | 2.34 | 1.27 | 4.15 |
Financials of Kilitch Drugs (India) Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 235 |
| Expenses + | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 199 |
| Operating Profit | -2 | -4 | -1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 37 |
| OPM % | -9% | -19% | -2% | 11% | 9% | 1% | 8% | 9% | 13% | 16% | 16% | 16% |
| Other Income + | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 11 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 |
| Depreciation | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 4 |
| Profit before tax | -1 | -12 | -9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 39 |
| Tax % | -70% | -4% | -5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | 24% |
| Net Profit + | -0 | -11 | -9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 30 |
| EPS in Rs | -0.10 | -3.89 | -3.09 | 1.72 | 1.15 | 0.25 | 1.09 | 2.17 | 3.08 | 4.17 | 7.63 | 8.63 |
| Dividend Payout % | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Kilitch Drugs (India) Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
| Reserves | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings + | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 89 |
| Other Liabilities + | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 89 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed Assets + | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 67 |
| CWIP | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 140 |
| Investments | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 75 |
| Other Assets + | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 176 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
Financials of Kilitch Drugs (India) Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | -2 | 18 | 24 |
| Cash from Investing Activity + | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 | -100 |
| Cash from Financing Activity + | -0 | 0 | -0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 | 82 |
| Net Cash Flow | -39 | -2 | -0 | 2 | 3 | -5 | 10 | -2 | 10 | -1 | -9 | 6 |
| Free Cash Flow | -10 | -26 | -0 | -2 | -19 | -6 | 9 | -2 | -1 | -8 | -29 | -76 |
| CFO/OP | 430% | -442% | -202% | 25% | 60% | 1,598% | 877% | 79% | 39% | 23% | 82% | 94% |
Financials of Kilitch Drugs (India) Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory Days | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 | 33 |
| Days Payable | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 | 230 |
| Cash Conversion Cycle | 243 | 241 | 96 | 79 | 89 | 89 | -367 | -79 | -48 | 50 | 20 | -11 |
| Working Capital Days | 197 | 234 | 115 | 93 | 37 | 22 | -223 | -40 | -4 | 30 | 56 | 130 |
| ROCE % | -10% | -9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% | 14% |
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…